

STATE OF KANSAS
KANSAS PHARMACY BOARD

**NOTICE OF PUBLIC HEARING ON PROPOSED
ADMINISTRATIVE REGULATION**

A public hearing will be conducted at 9:00 a.m., on the 3rd day of February, 2009, at the Landon State Office Building, 900 SW Jackson, Room 106, Topeka, Kansas 66612, to consider the addition of K.A.R. 68-20-23 as a permanent regulation of the Kansas Pharmacy Board.

This 60-day notice of the public hearing shall constitute a public comment period for the purpose of receiving written public comments on the proposed adoption of K.A.R. 68-20-23. All parties may submit written comments prior to the hearing to the Executive Secretary of the Kansas Pharmacy Board, Debra Billingsley, pharmacy@pharmacy.ks.gov or Landon State Office Building, 900 SW Jackson, Room 560, Topeka, Kansas 66612-1231. All interested parties will be given a reasonable opportunity to present their views orally on the amendment of the regulation during the hearing. In order to give all parties an opportunity to present their views, it may be necessary to request each participant to limit any oral presentation to five minutes.

Any individual with a disability may request accommodation in order to participate in the public hearing and may request the regulation and economic impact statement in an accessible format. Requests for accommodation to participate in the hearing should be made at least five working days in advance of the hearing by contacting the Kansas Pharmacy Board, Landon State Office Building, 900 SW Jackson, Room 560, Topeka, Kansas 66612-1231, (785) 296-4056. Handicapped parking is located on the west and north sides of the building, and the north entrance to the building is accessible to individuals with disabilities.

The regulation is proposed for permanent adoption. A summary of the regulation is as follows:

K.A.R. 68-20-23. N-Benzylpiperazine included in schedule I. N-Benzylpiperazine (BZP), including its salts, isomers, and salts of isomers, shall be classified as schedule I controlled substance.

Copies of the regulation and the economic impact statement may be obtained from the Kansas Pharmacy Board, Landon State Office Building, 900 SW Jackson, Room 560, Topeka, Kansas 66612-1231, (785) 296-4056, or by accessing the Board's website at <http://www.kansas.gov/pharmacy/proposedregs.html>.

Debra Billingsley
Executive Secretary

STATE OF KANSAS
KANSAS PHARMACY BOARD

ECONOMIC IMPACT STATEMENT

Pursuant to K.S.A. 77-420(b), the Kansas Pharmacy Board submits the following description of the economic impact of K.A.R. 68-20-23 as a temporary regulation.

1. This regulation identifies that N-Benzylpiperazine (BZP), including its salts, isomers, and salts of isomers, shall be classified as a schedule I controlled substance.
2. The proposed regulation is not mandated by federal laws.
3. No new costs will be borne by pharmacists, pharmacy technicians, small employers, or others.
4. The Board is not aware of any less costly or less intrusive methods to achieve the stated purpose and thus none were considered.
5. This is not a proposed environmental regulation.

68-20-23. N-Benzylpiperazine included in schedule I. N-Benzylpiperazine (BZP), including its salts, isomers, and salts of isomers, shall be classified as a schedule I controlled substance. (Authorized by and implementing K.S.A. 65-4102; effective, T-_____, _____; effective P-_____.)

DEPT. OF ADMINISTRATION

OCT 03 2008

APPROVED

ATTORNEY GENERAL

OCT - 7 2008

APPROVED BY 